Ignyta, Inc.
News
Prometheus Biosciences, Inc. (NASDAQ:RXDX) Receives $153.36 Consensus Price Target from Brokerages
Ticker Report Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) have earned a consensus rating of Hold from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and four have ...\n more…
Brokerages Set Prometheus Biosciences, Inc. (NASDAQ:RXDX) Target Price at $153.36
Zolmax Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) has been given an average recommendation of Hold by the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and four have given a buy recommendation ...\n more…
Merck Completes Acquisition of Prometheus Biosciences, Inc.
Business Wire Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (Prometheus) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or...\n more…
Artia Global Partners LP Acquires Shares of 22,321 Prometheus Biosciences, Inc. (NASDAQ:RXDX)
Zolmax Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical companys stock...\n more…
Avidity Partners Management LP Invests $22.44 Million in Prometheus Biosciences, Inc. (NASDAQ:RXDX)
Ticker Report Avidity Partners Management LP purchased a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 204,000 shares of the ...\n more…
Point72 Asset Management L.P. Boosts Stock Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)
Ticker Report Point72 Asset Management L.P. boosted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) by 113.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,266,083 shares of the biopharmaceutical ...\n more…